Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.62 |
| ▸ | BCL6 | P41182 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264817 | 0.91 | BRD4 (0.70) | BRD4JAK2CYP3A4JAK1JAK3 | |
| SCHEMBL270949 | 0.90 | BRD4 (0.49) | BRD4 | |
| SCHEMBL271306 | 0.85 | JAK2 (0.56) | BRD4JAK2CYP3A4JAK1JAK3 | |
| SCHEMBL760315 | 0.85 | CDK2 (0.49) | BRD4JAK2CYP3A4JAK1JAK3 | |
| SCHEMBL271520 | 0.84 | AURKA (0.51) | BRD4JAK2JAK1JAK3KDR | |
| SCHEMBL270986 | 0.83 | BRD4 (0.59) | BRD4BCL6 | |
| SCHEMBL265286 | 0.82 | BRD4 (0.84) | BRD4 | |
| SCHEMBL271208 | 0.81 | BRD4 (0.63) | BRD4 | |
| SCHEMBL12109505 | 0.81 | BRD4 (0.65) | BRD4JAK2JAK1JAK3EPHA2 | |
| SCHEMBL266088 | 0.80 | BRD4 (0.56) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | BRD4 142/4885BCL6 747/4885JAK2 1/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | BRD4 1036/4885BCL6 148/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.